NCT00163540已完成4 期
Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225)
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Pfizer
- 试验地点
- 2
研究概览
简要总结
The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225. In Study 225, two vaccinations were given using a rapid immunization schedule 12 ± 2 days apart.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 17 Years 至 66 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects who:
- •received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225
- •understand the nature of the study, agree to its provisions and provide written informed consent
- •are clinically healthy (i.e. the physician would have no reservation vaccinating with FSME-IMMUN 0.5 ml outside the scope of the clinical trial)
- •have a negative pregnancy test result at the first medical examination (if female and capable of bearing children)
- •agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
- •agree to keep a Subject Diary
排除标准
- •Subjects who:
- •have already been administered a third TBE vaccination elsewhere since receiving two vaccinations in Study 225
- •have a history of infection with, or vaccination against, other flaviviruses since participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis)
- •have had an allergic reaction to one of the components of the vaccine since participation in Study 225
- •suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a form of treatment (e.g., systemic corticosteroids) that can be expected to influence immunological functions
- •have a known or suspected problem with drug or alcohol abuse (>4 liters wine/week or equivalent doses of other alcoholic beverages)
- •have donated blood or plasma within 30 days of study entry
- •have received a blood transfusion or immunoglobulins within 30 days of study entry
- •are known to be HIV positive (an HIV test is not required specifically for this study)
- •are simultaneously participating in another clinical trial including administration of an investigational product
- •have participated in any other clinical study within 6 weeks prior to study start
- •have participated in another Baxter vaccine study in the past 6 months (with the exception of follow-up studies)
- •For female subjects: pregnancy or lactation
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 YearsEncephalitis, Tick-borneNCT00161850Pfizer615
已完成
2 期
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 YearsEncephalitis, Tick-borneNCT00161889Pfizer615
已完成
3 期
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersInfluenzaNCT01987011Green Cross Corporation420
已完成
2 期
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.COVID-19NCT05975060Novavax660
已完成
3 期
Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)Pneumococcal InfectionsNCT04384107Merck Sharp & Dohme LLC694